Alcobra Target of Unusually Large Options Trading (ADHD)
Shares of Alcobra (NASDAQ:ADHD) were the recipient of unusually large options trading activity on Thursday. Traders purchased 3,310 call options on the stock, American Banking News.com reports. This represents an increase of approximately 573% compared to the typical volume of 492 call options.
A number of analysts have recently weighed in on ADHD shares. Analysts at FBR Capital Markets initiated coverage on shares of Alcobra in a research note on Wednesday. They set a “market perform” rating and a $23.00 price target on the stock. Separately, analysts at Piper Jaffray initiated coverage on shares of Alcobra in a research note on Monday, August 4th. They set an “overweight” rating and a $42.00 price target on the stock. Finally, analysts at Roth Capital initiated coverage on shares of Alcobra in a research note on Friday, August 1st. They set a “buy” rating and a $40.00 price target on the stock. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $32.29.
Shares of Alcobra (NASDAQ:ADHD) traded down 2.69% on Thursday, hitting $19.19. The stock had a trading volume of 151,331 shares. Alcobra has a 1-year low of $12.29 and a 1-year high of $26.96. The stock has a 50-day moving average of $19.10 and a 200-day moving average of $18.87. The company’s market cap is $262.2 million.
Alcobra (NASDAQ:ADHD) last released its earnings data on Monday, August 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.57). Analysts expect that Alcobra will post $-2.16 EPS for the current fiscal year.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (NASDAQ:ADHD), a common and morbid neuropsychiatric condition in children and adults.
Receive News & Ratings for Alcobra Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.